In this episode of Cutaneous Miscellaneous, Dr. Nicholas Brownstone welcomes Dr Peter Lio, founding director of the Chicago Integrative Eczema Center, to discuss the 3 FDA-approved biologics for atopic dermatitis, focusing on the latest addition, lebrikizumab. With more options for atopic dermatitis come new challenges for clinicians. Dr Lio offers practical insights on differentiating dupilumab, tralokinumab, and lebrikizumab, all targeting the IL-4/13 pathways but with distinct binding and dosing characteristics. He explains his decision-making process for starting biologics, discusses patient education on safety, and provides valuable strategies for navigating insurance. For residents, Dr Lio shares tips on gaining hands-on experience with biologics, staying updated on upcoming treatments like OX40 inhibitors, and key board review topics, including the differences in binding sites, side effects, and dosing protocols of these agents. Tune in to the full episode for high-yield information and clinical pearls for dermatologists navigating the evolving landscape of atopic dermatitis treatments! Need help keeping track of all the approved medications discussed in this episode? Check out our quick-reference chart that includes essential details on FDA-approved ages, dosing, and mechanisms of action for biologics in atopic dermatitis and psoriasis.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related